<DOC>
	<DOCNO>NCT00752544</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability three different dos TMC435350 compare placebo healthy Japanese male .</brief_summary>
	<brief_title>TMC435350-TiDP16-C109 : A Safety Study TMC435350 Oral Solution Containing Either 100 , 200 400 mg Equivalent TMC435350 Placebo Healthy Japanese Male Volunteers</brief_title>
	<detailed_description>This Phase I , double-blind ( neither physician volunteer know dose study medication ) , randomize ( study medication assign chance ) , placebo-controlled ( dose without study medication present ) trial determine safety , tolerability plasma pharmacokinetics ( amount medication blood ) TMC435350 single multiple oral dos healthy male Japanese volunteer . 100 mg , 200 mg 400 mg dos give oral solution . Six ( 6 ) dos give 3 day follow-up first second dose . Additional follow-up do 3 day last dose approximately 2 4 week last dose .</detailed_description>
	<mesh_term>Simeprevir</mesh_term>
	<criteria>Healthy Japanese male volunteer age 20 55 year Japanese healthy volunteer reside outside Japan five year whose parent maternal paternal grandparent Japanese Nonsmoking smoking 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior selection Normal weight define Body Mass Index ( BMI : weight kg divide square height meter ) 18.0 30.0 kg/m2 Body weight 50 kg screening Informed Consent Form ( ICF ) sign voluntarily trialrelated activity Normal 12lead electrocardiogram ( ECG ) screen Healthy basis medical evaluation reveals absence clinically relevant abnormality . Healthy volunteer must follow characteristic : Past history heart arrhythmia ( extrasystoli , tachycardia rest ) baseline prolongation QTc interval &gt; 450 m , history risk factor Torsade de Pointes syndrome ( hypokalemia , hypomagnesemia , family history long QT Syndrome ) echographically suspect cardiomyopathy History evidence current use alcohol , barbiturate , amphetamine , recreational narcotic drug use investigator 's opinion would compromise healthy volunteer 's safety and/or compliance trial procedure Hepatitis A , B , C infection ( confirm hepatitis A antibody , hepatitis B surface antigen , hepatitis C virus antibody , respectively ) human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection screen A positive urine drug test screening . Urine test presence amphetamine , benzodiazepine , cocaine , cannabinoids , opioids Currently active underlie gastrointestinal , cardiovascular , neurologic , psychiatric , metabolic , renal , hepatic , respiratory , inflammatory , infectious disease Any history clinically relevant skin disease , limited , dermatitis , eczema , drug rash , drug allergy , psoriasis , food allergy , urticaria History drug allergy , limited , sulfonamides penicillin , drug allergy Use concomitant medication , include herbal medication dietary supplement product contain Hypericum perforatum ( e.g . St. John 's wort ) , except paracetamol ( acetaminophen ) ibuprofen period 14 day first trial medication intake Participation another investigational drug trial within 30 day prior first intake trial medication Donation blood plasma within 60 day precede first intake trial medication</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>TMC435350</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>TMC435350-TiDP16-C109</keyword>
	<keyword>TMC435350-C109</keyword>
</DOC>